Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y(12) Assay in Patients With Coronary Artery Disease

Background: Vonoprazan is a potassium-competitive acid blocker increasingly used in Japan to prevent upper gastrointestinal bleeding in patients undergoing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). Cytochrome P450 (CYP) 3A4 is involved in the primary metabolism...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circ Rep
Hlavní autoři: Koga, Seiji, Ikeda, Satoshi, Akashi, Ryohei, Yonekura, Tsuyoshi, Kawano, Hiroaki, Maemura, Koji
Médium: Artigo
Jazyk:Inglês
Vydáno: The Japanese Circulation Society 2020
Témata:
Original article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7939790/
https://ncbi.nlm.nih.gov/pubmed/33693287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circrep.CR-20-0124
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky